NCT04724681 (WARD COVID-19) is a NA clinical trial of WARD CSS in Clinical Deterioration, sponsored by University Hospital Bispebjerg and Frederiksberg.

Who is sponsoring NCT04724681?

NCT04724681 is sponsored by University Hospital Bispebjerg and Frederiksberg.

What drugs are being tested in NCT04724681?

Interventions in NCT04724681: WARD CSS.

What condition does NCT04724681 study?

NCT04724681 studies Clinical Deterioration.

Is NCT04724681 still recruiting?

NCT04724681 is currently terminated. Last updated 1 June 2023.

Last reviewed 2023-06-01 · How we verify

NCT04724681: WARD COVID-19

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Continuous Wireless Monitoring of Vital Signs and Automated Alerts of Patient Deterioration in Patients Admitted With COVID-19 Infection

Terminated NA Last updated 1 June 2023

What this trial tests

NA trial testing WARD CSS in Clinical Deterioration in 97 participants. Terminated before completion.

Timeline

3 November 2020

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	University Hospital Bispebjerg and Frederiksberg
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	97
Start date	3 November 2020
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across Denmark

Drugs / interventions tested

WARD CSS

Conditions studied

Clinical Deterioration — all drugs for Clinical Deterioration →

Sponsor

University Hospital Bispebjerg and Frederiksberg

Who can join

18 and older, any sex, with Clinical Deterioration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

For patients admitted with COVID-19 infection, it is often difficult to predict if or when their clinical condition will deteriorate. However subtle changes in vital signs are usually present 8 to 24 hours before a life-threatening event such as respiratory failure leading to ICU admission, or unanticipated cardiac arrest. Such adverse trends in clinical observations can be missed, misinterpreted or not appreciated as urgent. New continuous and wearable 24/7 clinical vital parameter monitoring systems offer a unique possibility to identify clinical deterioration before patients condition progress beyond the point-of-no-return, where adverse events are inevitable. The primary aim of this study is to test the effect of continuous wireless vital signs monitoring with generation of real-time alerts through a purpose-built GUI, compared to standard EWS monitoring on the cumulative duration of any severely deviating vital signs

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Clinical Deterioration

Currently open trials in the same condition.

NCT06634147 — Prevention of Functional and Cognitive Impairment Through a Multicomponent Exercise Program in Hospitalized Older Adults · NA · recruiting
NCT05893420 — A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning · NA · active not recruiting

Other University Hospital Bispebjerg and Frederiksberg trials

Trials by the same sponsor.

NCT07060586 — The Effect of Sphenopalatine Ganglion Block on Headache and Vasalgia · NA · completed
NCT06911411 — PALLIATIVE ASSESSMENT COHORT IN THE GERIATRIC EMERGENCY SETTING · not yet recruiting
NCT06405750 — Left Atrial Appendage Arrhythmogenic and Thrombogenic Substrate · NA · recruiting
NCT06532825 — Cardiac Autonomic Dysfunction As a Sign of Irreversible Advanced Heart Failure · recruiting
NCT06184581 — Lithium Versus Lamotrigine in Bipolar Disorder, Type II · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04724681 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Bispebjerg and Frederiksberg
Last refreshed: 1 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04724681.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing